Introduction n
Crohn'ss disease is characterized by a chronic inflammation of the gastro-intesrinal tract.
Inn most patients with active disease remissions can be induced using corticosteroids or tumourr necrosis factor a (TNF-ot) neutralizing antibodies. However, such remissions aree oftentimes short-lived and about 50% of die patients treated with corticosteroids showw an early relapse. 4 Repeated infusions of TNF-neutralizing antibodies can maintain thee therapeutic effects in a significant number of patients,'' but long-term administration iss costly and can be immunogenic. Hence, there is a continued need for effective maintenancee therapy in Crohn's disease. Itt has been reported that subcutaneous administration of recombinant (r)IL-10 in
Substantiall evidence indicates that activated CD4 T helper 1 (TM)
Crohn'ss disease is safe, well tolerated and has some therapeutic efficacy. '' However, highh concentrations of rIL-10 {e.g. subcutaneous 20 ug/kg) are associated with adverse effectss such as headache and fever as well as overproduction of pro-inflammatory cytokines.""" Moreover, studies in healthy human volunteers 1 '' and Crohn's disease patients""" demonstrated that svstemicallv administered rIL-10 has a restricted half live (2.55 hours) and may have limited mucosal bioavailability-. The limitations of systemic rIL-100 therapy might be overcome by targeting 11,-10 production to the intestine using IL-100 gene transfer. CD4 cells are ideal earners for the IL-10 gene, because subsets of
9
Chapterr 5 CD44 cells have die capability to "home" to the intestine, which is mainly mediated by thee interaction of the integrin »4J3 7 and the mucosal addressin MAdCAM-1.~'
Becausee of the central role of IL-10 in controlling intestinal inflammation, we have soughtt to engineer human CD4' cells that constitutive]v produce IL-10 using a retroviral vectorr containing the IL-10 cDNA. We mvestigared whether these CD4 cells produced moree IL-10 compared with control cells and determined whether II, 10 production was activanon-dependent.. Furthermore, we studied the biological activity of the IL-10 transgenee and the gut-homing potential of the transduced CD4 cells.
Materiall and methods

Vectorss and viral production
Thee LZRSpBMN-IRKS-GFP retroviral plasmid (referred to as GFP) has been previously Island,, NY, ISA) supplemented with 10% fetal calf serum (FCS) (Biowhittaker, Vt'alkersville,, MO, 1'SA), 2 mM glutaminc. 10(1 I "/ml penicillin, and 100 mg/ml streptomycinn (GibcoBRL) under standard conditions (A^°C, 5% GOj. The packaging cellss were rransfecred with the retroviral plasmids using calcium phosphate precipitation
Kill l
Engineeredd T cells for IL-10 delivery to the gut (GibcoBRU)) as described elsewhere.'' Viral supernatants were harvested after two weeks off puromvein selection (Clontech), filtered using a 0.45 \xm filter (Nalge, Rochester, NV, USA)) and stored at -80°C. Virus utres were determined using NIH 3T3 lines, as previouslyy described. 21 Virus stocks with titres of W-K)'' IL'/ml were used for transductionn of human '1' cells. 
Retrovirall transduction of human T cells
Purificationn of transduced CD4 + T cells
Too obtain a purified CD4' cell subset, eight to ten days after transduction, ceils were stainedd with CD4-PU (Coulter-Immunotech, Marseille, Prance) and sorted in a 1ACS
Vantagee Cell Sorter (Becton Dickinson, CA. USA) into subsets of CD4 and GPP expressingg cells. After sorting, a double-positive population was purified to at least 90%.
'lliee sorted GPP" CD4" cells were expanded and cultured in the feeder mixture for furtherr analysis. 
Celll proliferation assays
Thee proliferation rate of the transduced CD4" T cells was measured at the same time 
Engineeredd T cells for IL-iO delivery to the gut
Inn separate experiments, the proliferation rate of increasing numbers (up to 5x10''/well) off sorted transduced CD4' cells was measured after stimulation with allogeneic monocytess (lxlfVySvell). Monocytes were isolated using Percoll (Pharmacia, L'ppsala, Sweden)) density centnfugation (90% CD14"). Cells were cocultured in a final volume of 2000 p.1 of medium in 96-well round bottom plates (Costar).
Inn coculture experiments, autologous responder cells (cultured CD4* cells and fresh PBMCs)) (5xl0 4 /well) were isolated as described above and stimulated with monocytes (Amersham)) and the incorporated radioactivity was determined as described.
Analysiss of IL-12 production by dendritic cells
DCss were generated from PBMCs as described previously. 
Adhesionn assay
Wee investigated whether transduced CD4" cells were able to bind to the mucosal To rest this biologicall activity, we performed a H-thymidine incorporation assay on our transduced 109 9
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celll cultures in parallel to the cytokine production assays after 48 h of ocC.D3/CD28
activation.. Figure 4A shows the stimulation index of 2 representative donors of a total of 6.. 'Hie IL-KI-GFP CD4 cells had a reduced proliferative response to aCD3/CD28 activationn in comparison to control GFP CD4 cells. Similar results were obtained after 722 h of cxCD3/CD28 activation (data not shown). These data indicate that the increased productionn of IL-10 bv activated IL-IO-GFP CD4 cells, as shown in figure 3 , reflects an increasedd IL-10 production per cell, as it could not he ascribed to an increased number of cellss due to proliferation. In addition, IL-10-GFP CD4~ cells had a blunted proliferative responsee when stimulated with allogeneic monocytes in sharp contrast to the control GFPCD4"" cells ( figure 4B) .
Too obtain the effect of rIL-10 on alloantigen induced proliferation of responder cells
(t-.g.(t-.g. cultured CD4
' cells and fresh PBMCs), these cells were stimulated with purified allogeneicc monocytes. In figure 5A , it is shown that rIL-10 inhibited the proliferative responsess in a dose-dependent fashion. Significant inhibitory effects were already observedd at rIL-10 concentrations of 1.25 ng/ml (p=0.049 versus no rIL-10 added) and 
